3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

IMPROVEMENTS IN FACIAL LIPOATROPHY AT 48 WEEKS FOLLOWING SUBSTITUTION OF A THYMIDINE ANALOG WITH TENOFOVIR DF (TDF) OR ABACAVIR (ABC): A RANDOMISED, OPEN-LABEL STUDY IN PERSONS WITH LIPOATROPHY AND VIROLOGICAL SUPPRESSION ON HAART

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. TuPeLB2.3C02

Benn P.¹, Sauret V.², Cartledge J.¹, Ruff C.², Sabin C.³, Moyle G.⁴, Richards R.², Reilly G.⁵, Edwards S.^1
1Dept GUM, Mortimer Market Centre, Camden PCT, London, United Kingdom, ²Dept Medical Physics, University College Hospital, London, United Kingdom, ³Primary Care & Population Sciences, RFUCLMS, London, United Kingdom, ⁴Chelsea & Westminster Hospital, London, United Kingdom, ⁵Gilead Sciences, London, United Kingdom

METHODS: We completed a sub-study of 47 lipoatrophic HIV-infected subjects as part of the RAVE study. Patients were on HAART (11 with AZT and 36 d4T), naïve to ABC and TDF and had a current viral load <50c/mL for >24-weeks. Limb fat was measured by dual-energy x-ray absorptiometry (DEXA) and 3-D facial laser imaging was performed at baseline and 48 weeks to detect changes in facial volume overlying the forehead and both cheeks. Associations between the face imaging parameters and other measures of body composition at 48-weeks was examined using Spearman's rank correlation.

RESULTS: 24 patients received ABC and 23 TDF. At baseline 39/47 (84.8%) reported facial lipoatrophy. At week 48 the mean volume difference overlying the forehead area was – 138 mm³ (SD 347) and both cheek areas was 2539 mm³ (SD 5346), with no difference by treatment group (p=0.41 and p=0.88, respectively). The mean volume increase overlying the cheek area is similar to that observed following collagen injections. There was no significance difference in the proportion of patients reporting improvement/no change (68.1%) in the severity of facial lipoatrophy at week 48; with no difference by treatment group (p=0.83, Chi-squared test). Mean limb fat at baseline was similar at randomisation for the ABC and TDF groups (mean [SD]: 2.9[0.9] kg and 3.4 [2.1] kg respectively). At week 48 there were similar increases in limb fat in both treatment groups (mean 0.36 kg). There was a significant correlation between the total cheek volume change and limb fat change (p=0.004). This remains significant after adjusting for weight gain (p=0.02).

CONCLUSIONS: In lipoatrophic HIV-infected adults, switching from a thymidine analog to ABC or TDF for 48 weeks leads to similar significant improvements in both limb fat and facial lipoatrophy. Changes in total facial cheek volume significantly correlate with increases in limb fat shown by DEXA imaging.

Download PDF of this abstract.

050724
Clinical | TuPeLB2.3C02 | P. Benn
Lipoatrophy

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.